Our objective here was to determine whether oral bisphosphonate (BP) use is associated with the incidence of agerelated macular degeneration (AMD). We performed a population-based study using electronic health records from UK primary care (Clinical Practice Research Datalink). A cohort of 13,974 hip fracture patients (1999-2013) was used to conduct (1) a propensity score-matched cohort analysis and (2) a nested case-control analysis. Hip fracture patients were aged ࣙ50 years without AMD diagnosis before hip fracture date or in the first year of follow-up. Among 6208 matched patients and during 22,142 person-years of follow-up, 57 (1.8%) and 42 (1.4%) AMD cases occurred in BP users and non-BP users, respectively. The survival analysis model did not provide significant evidence of a higher risk of AMD in BP users (subhazard ratio: 1.60; 95% confidence interval (CI): 0.95-2.72; P = 0.08), although there was a significant increased risk among BP users with high medication possession ratio (MPR) (top quartile) relative to non-BP users (odds ratio: 5.08, 95% CI: 3.11-8.30; P < 0.001, respectively). Overall, oral BP use was not associated with an increased risk of AMD in this cohort of hip fracture patients, although the risk increased significantly with higher MPR. More data are needed to confirm these findings.
Introduction
Age-related macular degeneration (AMD) is irreversible central vision loss, involved in 8.7% of all blindness worldwide. 1 It is the leading cause of permanent vision impairment and the most prevalent condition of ocular deterioration in the population aged over 50. 2 In the United Kingdom, there are around an estimated 71,000 new cases of late AMD per year, 3 contributing to the total £1.6 billion 4 annual cost of AMD. AMD is subdivided into dry (nonneovascular and nonexudative) and wet (neovascular and exudative) forms and is characterized by distortion of central vision, black or gray patches affecting the central field of vision, and difficulty in reading, driving, or seeing fine detail. 2, 5 doi: 10.1111/nyas.13589
Osteoporosis is a musculoskeletal disease defined by low bone mass and degradation of bone microarchitecture, culminating in an escalation in bone frailty and susceptibility to fracture. It is estimated to affect approximately one-tenth of women aged 60 and up to two-thirds of women aged 90, 6 with approximately 200 million women affected worldwide. Several parts of the skeleton are affected, with the hip being a common site sustaining a fracture, with around 65,000 fracture cases reported each year across England, Wales, and Northern Ireland. 7 The molecular events and their sequence leading to AMD are poorly understood. Hydroxyapatite (calcium and phosphate) spherules have now been identified as key components in the development of the disease. 8 Bisphosphonates (BPs), the first line of treatment for osteoporosis, could increase the dissolution of hydroxyapatite crystals, and thus they could reduce the risk of AMD. Our aim in this study was to investigate whether the risk of developing AMD is affected by the oral BP use in a real-world population-based cohort of incident hip fracture patients.
Methods

Data source and sample size
This study was carried out using data from the Clinical Practice Research Datalink (CPRD). The CPRD contains primary care data from 674 UK practices and includes 11.3 million patients, covering 7% of the UK population. 9 Many aspects of the CPRD have been well validated, and it has been applied for a variety of safety studies examining BPs. [10] [11] [12] A cohort of patients with an incident hip fracture was retrieved for the period 1999-2013. Mortality data were matched to the Office for National Statistics database.
Study design
Baseline characteristics were collected closest (during the previous 12 months) to the hip fracture event. We used a cohort study design among patients followed from hip fracture until the earliest date of either being lost to follow-up, death, or July 31, 2013. A nested case-control study was also conducted to estimate the association between BP dose and risk of AMD.
Exposure
Post-index-date prescription records were used to categorize patients as either oral BP users or nonusers. Oral BP use was further classified according to defined daily dose (DDD) and medication possession ratio (MPR). MPR was calculated as DDD between date of first BP prescription and outcome date (or last prescription). DDDs and MPRs were categorized into quartiles.
Immortal time bias is a common issue in pharmacoepidemiological studies. In the time from index date until receipt of BP, those in the BP-user group cannot have the outcome by design, as otherwise they would have been classified as a non-BP user. To address this issue, we used time-varying exposures in the survival model, where the time period before becoming a BP user was reclassified as nonuse for those in the oral BP user group.
Outcome
Our defined outcome was AMD recorded at least 1 year after follow-up initiation. Cases were identified using standard UK clinical terminology "read" codes: F425100 ("dry senile macular degeneration"), F425200 ("wet senile macular degeneration"), F425z00 ("degeneration of macula or posterior pole, not otherwise specified"), F425.00 ("degeneration of macula and posterior pole"), F425.11 ("senile macular degeneration"), and F425000 ("unspecified senile macular degeneration").
Exclusion criteria
Patients younger than 50 years at hip fracture were excluded ( Fig. 1) , given their low risk of AMD 5 and that BPs are infrequently prescribed in younger individuals. Patients were excluded if they had a diagnosis of AMD either before the index date or during the first year of follow-up. Patients with a BP prescription or who transferred out of the CPRD before index hip fracture date were also excluded, as were patients with an index hip fracture occurring after July 31, 2012, given that they had insufficient follow-up time (<1 year) to experience the outcome. Finally, patients on nonnitrogen-containing BPs (etidronate), parenteral antiresorptives (zoledronic acid, pamidronate, and denosumab), and teriparatide (a bone-forming agent) were not included in the study, because the number of those patients was negligible.
Confounders
Factors considered potential confounders were calendar year of hip fracture, age, gender, body mass index (BMI), smoking (no, ex-smoker, and smoker), Drug confounders were antiarrhythmics, antidepressants, antiepileptics, antiparkinsonians, anxiolytics, proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy, selective estrogen receptor modulators, strontium ranelate, calcium, nonocular corticoids, ocular corticoids, and insulin. Denosumab and teriparatide were not prescribed to our study population and were not included in the analysis. Comorbidity confounders were Charlson comorbidity index (none, mild (1-2), moderate (3-4), or severe (ࣙ5)), asthma, inflammatory bowel disease, hypertension, hyperlipidemia, ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, cancer, cataract surgery, and type 1 and type 2 diabetes.
Missing data
Confounders with missing values after applying exclusion criteria and before using propensity score matching were BMI (101, 21.1%), smoking (900, 9.1%), and drinking (1729, 17.4%). They were imputed to avoid the exclusion of a large number of patients from the original sample. We generated a single imputed dataset using a chained equation across 50 iterations to reach a stationary distribution. We included all confounders, BP exposure, and the AMD diagnosis in the imputation process.
Statistics
Standard descriptive statistics were used to describe the characteristics and follow-up time of our sample. A propensity score for BP use was calculated using a logistic regression model, 13, 14 which included all confounders. BP users were matched to non-BP users on the logit of the propensity score, using a caliper width of 0.2 of the standard deviation of the logit of the propensity score. 15 A matching ratio of 1:1 was used. 16 We assessed standardized differences between the two groups, with 10% or more considered to be suggestive of imbalance. 17 Occurrence of AMD between BP users and non-BP users was evaluated after matching using two-tailed Fisher's exact tests. Kaplan-Meier survival curves were drawn for AMD incidence, and differences among BP exposures were compared using the log-rank test. 18 A multivariable competing-risk regression (death as competing event) was fitted to estimate the effect of BPs on AMD occurrence, 19, 20 the output of which was a sub-distributional hazard ratio (sHR) and 95% confidence interval (CI), adjusted for the pairing of patients in the matching process. The CI was informed using robust variance estimators assuming that observations were independent across groups (pairs of matched patients) but not necessarily within groups. 21 A time-to-exposure variable was calculated, splitting follow-up time of BP users into non-BP users and BP user (when the patient became a user) so as to account for any lag between index date and BP initiation. Effect of BP dose was assessed within a nested case-control study using DDDs and MPR. Each AMD case was matched to 20 controls using the propensity scores obtained previously. A caliper width of 0.2 was again applied. A conditional logistic regression model was fitted to ascertain how the risk of AMD was associated with the degree of exposure to BP in terms of quartiles of prescribed daily dose and MPR. This yielded odds ratios (ORs) and 95% CI, adjusted for matched cases and controls.
Analyses were conducted using the Stata version 13.1 statistical software (StataCorp, College Station, TX). Matching on BP was performed using the R Package "MatchIt," 22 while matching nested cases with controls used "Matching." 23 
Results
Descriptive statistics
Of the 13,974 hip fracture patients, 4035 (28.9%) were excluded before matching (Fig. 1) . Of the 9939 patients meeting the inclusion criteria, 3105 (31.2%) were BP users. AMD developed in 152 patients. Of them, 57 (37.5%) were on BP. The median time on BP until an AMD event was 2.9 years (0.5-8.9 years).
For the competing risk analysis, 3104 BP users were matched 1:1 to 3104 non-BP users, and, of these matched patients, 99 developed AMD.
For the nested case-control study, all 99 patients who developed AMD were matched 1:20 to 1980 controls who did not develop AMD. Of the 99 AMD cases, 57 (57.6%) were BP users compared with 951 (48.0%) in the 1980 matched controls.
Matching on BP
A total of 3104 BP users were matched 1:1 to a non-BP user (Table 1) . Covariate balance was improved after matching compared with before matching; the standardized differences for all the covariates were less than 10%, indicating acceptable balance. For example, before matching, the difference between non-BP and BP users for women was unbalanced (SMD = 0.31), and after matching that difference achieved an appropriate balance less than 10% (SMD = 0.04). After matching, there were 42 (1.4%) and 57 (1.8%) AMD cases among non-BP and BP users, respectively. The number of AMD cases according to patient characteristics, drug confounders, and comorbidity confounders is shown in Table 2 . There were more AMD cases in women, nonsmokers, current drinkers, and individuals using antidepressants, PPIs, or NSAIDs. There were also (independent of BP consumption) more AMD cases in those with hypertension. BP use was associated with more cases among men, former drinkers, antiepileptic users, PPI users, those with chronic renal failure, and type 2 diabetes. However, the only statistically significant differences found were for drinking (P = 0.02) and NSAID consumption (P = 0.04). Person-years of follow-up were 11,793 and 10,350 among non-BP and BP users, respectively. At year 5, there were 772 and 926 patients at risk for AMD, and 25 and 32 had developed AMD, respectively.
Survival probability of AMD
The Kaplan-Meier probability of AMD was not significantly different between non-BP and BP users (P = 0.13) (Fig. 2) . According to the Kaplan-Meier estimator, one in 100 hip-fracture patients would develop AMD in 5 years for non-BP users, compared with two in 100 for BP users. Therefore, the probability of not experiencing AMD, sometime after Using multivariable competing risk survival models, there was weak evidence of an increased risk of AMD development among BP users (sHR: 1.6; CI: 0.9-2.7; P = 0.08). Conditional logistic regression analysis on DDDs showed a trend increasing across the quartiles, which become significant for the third and fourth quartiles (OR 75th : 2.8, CI: 1.6-4.9, P < 0.01; OR 100th : 3.9, CI: 2.3-6.6, P < 0.01) (Fig. 3) . A similar ascending trend was observed for the quartiles of MPR, achieving significance for the highest quartile (OR 100th : 5.1, 3.1-8.3, P < 0.01) (Fig. 3) .
Discussion
We found that, in an incident hip fracture cohort, oral BP use was not overall significantly associated with increased risk of AMD. After matching, there were 42 (1.4%) versus 57 (1.8%) AMD cases among non-BP compared with BP users, equating to a low and nonsignificant absolute risk difference of 0.49% (CI: -0.13% to 1.11%; P = 0.06) (six more cases per 1000). However, the increased risk became somewhat greater and statistically significant among BP users who had a high MPR. According to our results, one AMD case at 5 years would be prevented if 12 hip fracture patients in the top quartile of MPR avoided BP treatment for longer than 1 year. To our knowledge, there is only one previous study analyzing the risk of AMD in patients taking oral BP. 24 This study used data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, which captures spontaneous adverse drug reactions. Two patient cohorts from Canada were also included, covering the period 2009-2013 for the cases and 2000-2007 for the controls. This study found a higher risk of developing wet AMD in BP users, although a caveat to these findings has to be that the selection of patients was limited to reported cases to FAERS without a clear definition of AMD for a disproportionality analysis. In addition, although this prior study conducted a case-control and a self-controlled case series analysis, this was limited to patients with wet AMD or controls without any type of AMD (dry, wet, or unspecified) selected among those visiting the ophthalmologist, and as such was not population based or inclusive of dry and unspecified AMD cases. Additionally, some concerns can arise when using different time periods for cases versus controls, and, despite the fact that their results reached significance, the magnitude of the effect was marginal. 25 Several risk factors have been identified as being associated with the development of AMD, with age being the strongest. However, the pathogenesis is not well understood. Inflammation may play a significant role, and, recently, hydroxyapatite (calcium and phosphate) spherules, which are commonly found in bones and teeth, have been identified as a key player in the development of the disease. 8 In terms of a potential mechanism of effect, ocular inflammatory reactions have been described in patients on BP treatment. Inflammatory proteins, such as interleukins, have also been linked to AMD development, [26] [27] [28] [29] [30] [31] and BPs could cause systemic release of cytokines and other acute-phase proteins. Moreover, a causative link between BPs and inflammatory ocular events is likely, based on reports of inflammatory eye reaction relapses after affected patients were rechallenged with the same or another BP. 32 If inflammation is indeed the cause, it begs the question why AMD is not a common complication in patients with inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, or sarcoidosis. The explanation could be that the inflammation alone is not sufficient by itself but requires the presence of hydroxyapatite spherules, which could be the critical factor in the development of AMD. Interestingly, BPs could not only retard the growth but also increase the dissolution of hydroxyapatite crystals, 33 in which case they would be expected to provide some protective effect. Our results did not show any beneficial effects of nitrogencontaining oral BPs on the incidence of AMD. On the other hand, there is no convincing explanation for the increased risk with higher DDDs and MPR. Therefore, if there is an association between their use and AMD, this association may not be a causal one.
Another plausible mechanism, and one opposed to our results (increased risk with higher DDDs and MPR), which could relate BP use to a reduced risk of AMD is their potential antiangiogenic effects, especially in the wet form of AMD, where antivascular endothelial growth factor intravitreal agents are the first line of treatment. In vitro, administration of BPs (alendronate and etidronate) on cultured retinal pigment epithelial cells reduced the expression of a number of angiogenic factors. 34 Additionally, in two pilot, nonrandomized studies of relatively short duration (6 and 24 months), administration of 5 mg alendronate daily in patients with wet AMD showed promising results. 35, 36 BPs have been demonstrated to stop bone loss and significantly reduce the occurrence of fractures in individuals with osteoporosis, and, consequently, they are the most extensively prescribed antiresorptive drugs. 37 Although they have been associated with some rare and severe adverse effects (atypical femur fractures and osteonecrosis of the jaw), the real-world antifracture benefit to patients at high risk of fracture far exceeds the potential risks. 38 
Strengths and limitations
There are multiple strengths to our current study. First, we conducted the analysis in a population of hip fracture patients for whom BP treatment is recommended for the secondary prevention of fragility fractures. Second, we used an incident user design to minimize biases associated with the inclusion of prevalent BP users. Third, despite the fact that our study was observational, we show an effect of BP after adjusting for a large number of confounders, including comorbidity, comedication, and other important factors, using propensity matching. Furthermore, we used a time-dependent exposure variable and conducted a subsequent nested casecontrol analysis for assessing dose-response. Using a nested case-control analysis gave us an unbiased assessment, like the sHR obtained from the time to event analysis in the matched cohort, almost free of immortal time bias. 39 Included in the limitations is the fact that prescriptions in the CPRD may have been misclassified in terms of BP exposure owing to data entry errors by general practitioners and other potential sources of error in the use of electronic systems. 40 Nevertheless, given that we only included patients into the BP user cohort if they were newly treated, misclassification is probably low, given that the CPRD is presently well known and established in the routine of healthcare personnel. Another limitation is that the study is observational in nature, and unmeasured or unknown factors may have resulted in residual confounding (e.g., genetic risk factors 41 ). Furthermore, deprivation index, ethnicity, 42 and measurements of the marker of inflammation C-reactive protein were in the dataset but were not used, due to high levels of absence and/or inaccuracy. Misclassification of AMD cannot be ruled out, as well as the further subdivision between wet and dry categories, with many patients included in the category of unspecific. For this reason, we have not made distinctions between types of AMD. Furthermore, we may have potentially overestimated BP use, as the analyses were based only on prescription data, given that information on adherence is not captured in the CPRD. However, the nested case-control design allowed us to estimate the effect of BP dose in AMD occurrence. Finally, there is the possibility of detection bias, given that BP use is associated with one eye condition, therefore giving rise to the possibility that BP users were more likely than non-BP users to have an eye examination where early AMD could be diagnosed, although this is unlikely given that eye examination is not routine for patients on BPs or in those with a hip fracture.
Conclusions
Our study of incident hip fracture patients offers an external validation showing that, overall, oral BP use was not associated with increased risk of AMD in a cohort of hip fracture patients. However, we found increased risk with higher DDDs and MPR. More data are needed to confirm these findings.
